Navigation Links
Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
Date:9/17/2007

Collaboration validates unique HIV assay system that identifies potential

tRNA inhibitors

CARY, N.C. and BIRMINGHAM, Ala., Sept. 17 /PRNewswire-USNewswire/ -- Trana Discovery, a drug discovery company, today announced the development of a high throughput screening (HTS) assay for the identification of new compounds for the treatment of HIV. The HTS assay was developed in collaboration with Southern Research Institute, a research organization that conducts basic and applied preclinical drug research. This new assay gives pharmaceutical companies the ability to rapidly and efficiently screen vast libraries of compounds in order to identify those that interrupt the lifecycle of HIV through a novel mechanism of action -- the inhibition of transfer RNA (tRNA). This technology has the potential to discover new classes of medicines for the treatment of HIV that may overcome resistance mechanisms associated with current therapies.

To date in the U.S., about 30 drugs -- as single agents or as combination products -- for the treatment of HIV infections have been introduced by more than ten different companies. But collectively, these agents represent only five different classes working at just four different sites of action in the HIV replicative cycle. And despite the enhanced potency of the more recently introduced products, resistance continues to be a major challenge for managing patients with HIV.

There remains an unexploited target for antiretroviral drugs -- the disruption of human transfer RNA (tRNA) use by the virus during HIV replication. But until recently, several barriers, including the stability of the RNA-RNA binding during experimentation, had prevented exploration of tRNA as a drug target. Working in collaboration with Southern Research, Trana Discovery refined their technology to overcome those barriers in a HTS format, thus opening the way to discovery and development of HIV drugs that work by means of this novel mechanism of action.

At the state-of-the-art High Throughput Screening Center at Southern Research, the Trana Discovery RNA assay was adapted to the robotics platform. By using precision robotics, highly accurate low volume liquid handling devices, sensitive detectors and powerful data processing software, the HTS assay that was developed will allow researchers to quickly conduct millions of tests that identify active compounds. The data generated from a large screen like this provides the starting point for drug design and development. Using this newly validated assay, the HTS Center at Southern Research can screen 50,000 compounds per day.

"We consider the HIV HTS assay as a major breakthrough in the development of new techniques in the early-stage drug discovery and development process," said David Harris, director of Drug Discovery Business Development at Southern Research. "The addition of the tRNA assay platform adds to our service offerings that lead to the improvement of people's lives around the world."

Trana Discovery and Southern Research are currently developing other HTS assays to identity compounds that interrupt the lifecycle of bacteria, such as E.coli and Methicillin-resistant Staphylococcus aureus (MRSA).

"The development of the HTS assay validates that our technology can be adapted to the automated platforms used for high throughput screening, and signals a major step forward in its advancement," said Steve Peterson, CEO of Trana Discovery. The patented technology has been under extensive development at North Carolina State University. "We are now ready for the commercialization and licensing of this technology to discover new classes of compounds that will inhibit HIV via a unique mechanism of action," said Peterson.

Trana Discovery is seeking diverse collections of compounds or compounds with known bioactivity against HIV but unknown mechanism of action to identify candidates for drug development. Organizations interested in licensing the HIV uHTS assay should contact Trana at info@tranadiscovery.com or by calling 866-390-3452 (toll free) or +1-919-342-6192. Parties also interested in outsourcing screening using this assay may contact David Harris at Southern Research at d.harris@southernresearch.org or call 1-800-967-6774.

About Southern Research Institute

Southern Research Institute is a not-for-profit organization that conducts basic and applied research in the areas of preclinical drug discovery and drug development, advanced engineering, environmental research and energy production. To date, Southern Research has discovered six FDA-approved cancer drugs and discovered sox additional drugs that are currently in late stage preclinical and early clinical trials. No other company or institution has brought six of its own cancer drug discoveries to market. For more information, please visit http://www.southernresearch.org.

About Trana Discovery, Inc.

Trana Discovery is a drug discovery company whose technology identifies compounds that interrupt the lifecycle of pathogens through a novel mechanism of action -- the inhibition of transfer RNA (tRNA). The company enables exclusive rights to new classes of drugs used to treat serious bacterial, fungal and viral infectious diseases. The use of Trana Discovery technology can unlock the value -- human and financial -- hidden in drug compound libraries and can shorten the time between drug discovery and availability. Trana Discovery is commercializing technology that has been under development for nearly 20 years at North Carolina State University. The company is located in Cary, North Carolina. For more information, please visit http://www.tranadiscovery.com.

Media Contacts:

Karl von Gunten (919) 931-1434 Rhonda Jung (205) 581-2317

karlvongunten@tranadiscovery.com jung@southernresearch.org


'/>"/>
SOURCE Southern Research Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
2. Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer
3. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
4. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
7. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
8. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
9. Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric Academic Societies Annual Meeting
10. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
11. Southern Research Institute to Present at the 2007 American Association For Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Wegener Polyangiitis - Pipeline Review, H2 2015 ... - Pipeline Review, H2 2015, provides an overview ... report provides comprehensive information on the therapeutic development ... various stages, therapeutics assessment by drug target, mechanism ... molecule type, along with latest updates, and featured ...
(Date:2/4/2016)... 4, 2016 Global Immunology Market to ... drive long-term market growth Summary Immune-mediated ... chronic disorders that affect 5–7% of western populations. ... their symptoms and key patient demographics, they are ... pathways and an inappropriate immune response. Generally, disease-modifying ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
Breaking Medicine Technology:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Looking for ... may be at the tips of your toes. Foot massage, whether administered by a ... pure comfort and relaxation. The American Board of Multiple Specialties in Podiatry ...
(Date:2/5/2016)... San Rafael, CA (PRWEB) , ... February 05, 2016 , ... ... partnership with ChildLight Yoga Studio in Dover, NH to direct high-performance kids yoga training. ... on New Hampshire’s seacoast, just one hour from Boston. , ChildLight Yoga Studio founder ...
(Date:2/5/2016)... ... ... Give To Cure today announced that it is working with ... campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer’s Disease. ... device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. , Give ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... need. The event is scheduled to take place on February 27, 2016 from 9am ... care to community members in need. Each patient will be given the opportunity to ...
(Date:2/5/2016)... ... 05, 2016 , ... In sleep, when the defenses of the day are ... of patients with eating disorders is significant self-criticism, and consequently these patients experience this ... regarded as maladaptive means for coping with this unease, but also leads to a ...
Breaking Medicine News(10 mins):